Reviva Pharmaceuticals (RVPH) Oppenheimer 35th Annual Healthcare Life Sciences Conference (Virtual) 2025 summary

Company overview and development focus

• Focuses on novel therapies for diseases with narrow targets, with two molecules in development.

• Brilaroxazine is the lead candidate, in phase 3 for schizophrenia, with two large randomized trials completed.

• Long-term safety study completed; full data readout expected by early April.

• Plans to expand brilaroxazine development to bipolar disorder, major depressive disorder, and ADHD.

• Drug shows anti-inflammatory effects, relevant for comorbid conditions in neuropsychiatric patients.

Schizophrenia market and unmet needs

• Schizophrenia affects about 1% of the global population, with 24 million cases worldwide and 4 million in the U.S.

• Around 30% of patients partially respond or do not respond to current treatments.

• Top unmet needs are effective treatment for negative symptoms and improving treatment adherence.

• Discontinuation rates are a key comparative metric for antipsychotics.

Clinical trial results and efficacy

• Brilaroxazine showed 12%-16% discontinuation in acute trials and 35% in long-term, about 50% less than other antipsychotics.

• Targets key dopamine and serotonin receptors, as well as downstream neurotransmitters and inflammatory markers.

• In a pivotal phase 3 trial with 411 patients, high dose showed robust efficacy with a 10-point separation from placebo.

• Efficacy for negative symptoms was statistically significant within one week, outperforming other drugs.

• 78% of patients had significant improvement in CGI score, with lower dropout rates than competitors.